Formulary Decisions

Search for the outcome of decisions made by the Formulary Committee

Filter
Select filter(s)
Etanercept
Enbrel
Routinely available
NICE (TA455 (SMC 781/12))
30/05/2012

Indication

For the treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.

For the treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.

Therapeutic Area

Skin

Status Description

Routinely available in line with national guidance

Formulation

10mg and 25mg powder and sterile water for solution for injection for paediatric use

Comments

May 2012 - Included on the Additional List for the indication in question. Specialist Use only. July 2017 - NICE MTA advice: SMC advice 781/12 is superseded by NICE TA455. June 2019 (as per LJF) - Routinely available in line with national guidance. Included in the Additional List, for Specialist Use only.

Link to Advice

TA455 (SMC 781/12)

Advice Published

12/07/2017